Synthetic Biologics, Inc. announced that it has entered into a securities purchase agreement for the private placement of 275,000 Series C convertible preferred shares and 100,000 Series D convertible preferred shares at a price of $8 per share for gross proceeds of approximately $3 million with returning investor MSD Credit Opportunity Master Fund, L.P., a fund managed by MSD Partners, L.P. on July 28, 2022. The Series C convertible preferred shares and Series D convertible preferred shares have a conversion price of $1.22. The securities are subject to transfer restrictions.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.254 USD | -3.42% | -6.27% | -40.94% |
May. 23 | Theriva Biologics Gets Fast Track Designation for Pancreatic Cancer Treatment | MT |
May. 23 | Theriva Biologics, Inc Announces U.S. Food and Drug Administration Granted Fast Track Designation | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-40.94% | 4.39M | |
+16.73% | 123B | |
+13.04% | 107B | |
-5.80% | 24.01B | |
+2.62% | 22.59B | |
-10.09% | 18.16B | |
-40.52% | 16.84B | |
-14.00% | 16.23B | |
+1.18% | 13.43B | |
+24.18% | 11.32B |
- Stock Market
- Equities
- TOVX Stock
- News Theriva Biologics, Inc.
- Theriva Biologics, Inc. announced that it expects to receive $3 million in funding from MSD Partners, L.P.